BRIEF published on 09/24/2024 at 23:05, 6 months 21 days ago Theralase Closes Non-Brokered Private Placement and Issues Stock Options Stock Options Non-brokered Private Placement Theralase Technologies Clinical Research Funding Bladder Cancer Study
PRESS RELEASE published on 09/24/2024 at 23:00, 6 months 21 days ago Theralase(R) Closes Non-Brokered Private Placement and Issues Stock Options Theralase Technologies Inc. successfully closes Non-Brokered Private Placement offering of units for cancer research and development Private Placement Pharmaceutical Company Theralase Technologies Inc. Clinical Study Cancer Research
BRIEF published on 09/19/2024 at 23:10, 6 months 26 days ago Theralase® Extends Warrants Share Purchase Warrants TSXV Extension Theralase Technologies Pharmaceutical Development
PRESS RELEASE published on 09/19/2024 at 23:05, 6 months 26 days ago Theralase(R) Extends Warrants Theralase Technologies Inc. plans to extend expiry date of 10,000,000 share purchase warrants from Sept 22, 2024, to Sept 22, 2027. Warrants issued in 2022 at $0.35/share. TSXV approval pending TSX Venture Exchange Expiry Date Extension Theralase Technologies Inc. Share Purchase Warrants Clinical Stage Pharmaceutical Company
BRIEF published on 09/03/2024 at 13:05, 7 months 13 days ago Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus Theralase Ruvidar Antiviral Drug HSV-1 Acyclovir
PRESS RELEASE published on 09/03/2024 at 13:00, 7 months 13 days ago Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus Theralase Technologies Inc. announces preclinical superiority of Ruvidar TM in destroying HSV-1 virus, seeking partnerships for commercial development Theralase Technologies Inc. Preclinical Study Partnerships Ruvidar TM HSV-1 Virus
BRIEF published on 08/28/2024 at 13:05, 7 months 19 days ago Rutherrin® Increases Efficacy of Chemotherapy for Lung Cancer Theralase® Technologies Inc. NSCLC Chemotherapy Rutherrin® Cisplatin
PRESS RELEASE published on 08/28/2024 at 13:00, 7 months 19 days ago Rutherrin(R) Increases Efficacy of Chemotherapy for Lung Cancer Theralase® announces significant enhancement of Cisplatin efficacy in chemotherapy resistant NSCLC using Rutherrin® drug formulation in preclinical studies. Combination therapy shows promising results for cancer treatment NSCLC Theralase Preclinical Studies Chemotherapy Rutherrin
BRIEF published on 08/21/2024 at 13:05, 7 months 26 days ago Theralase Demonstrates Activation of Rutherrin with Diabetes Drug Cancer Treatment Theralase Rutherrin Metformin ROS Production
PRESS RELEASE published on 08/21/2024 at 13:00, 7 months 26 days ago Theralase(R) Demonstrates Unique Ability to Activate Rutherrin(R) With Diabetes Drug Theralase Technologies Inc. announces innovative cancer treatment using Rutherrin activated by Metformin without light/radiation. Opens new patient care possibilities Innovation Theralase Technologies Inc. Cancer Treatment Rutherrin Metformin
Published on 04/16/2025 at 18:45, 1 hour 2 minutes ago New to The Street Renews Acurx Pharmaceuticals (NASDAQ: ACXP) for Exclusive 6-Month Media Series Including Nationwide TV, Earned Media, and Expanded Digital Reach
Published on 04/16/2025 at 15:45, 4 hours 2 minutes ago Organto Foods Closes Private Placement, Debt Settlement and Amendments to Convertible Notes
Published on 04/16/2025 at 15:15, 4 hours 32 minutes ago urban-gro, Inc. Awarded Three New Contracts with Fogo de Chão
Published on 04/16/2025 at 14:30, 5 hours 17 minutes ago LQR House Announces 35-for-1 Reverse Stock Split as Part of Strategic Nasdaq Compliance Initiative
Published on 04/16/2025 at 14:30, 5 hours 17 minutes ago enVVeno Medical to Participate in a Live Virtual Investor Closing Bell Segment
Published on 04/16/2025 at 18:41, 1 hour 5 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 04/16/2025 at 18:10, 1 hour 36 minutes ago Annual general meeting 2025: all proposals of the board of directors approved and Manja Greimeier elected
Published on 04/16/2025 at 18:00, 1 hour 46 minutes ago Mikron shareholders approve all proposals of the Board of Directors
Published on 04/16/2025 at 17:59, 1 hour 48 minutes ago Funding Circle Holdings plc: POS-Transaction in Own Shares
Published on 04/16/2025 at 18:42, 1 hour 4 minutes ago Deezer unveils new features to offer music fans an even more personalized experience
Published on 04/16/2025 at 17:46, 2 hours 1 minute ago Covivio - Q1 2025 activity: +5.4% revenue growth year-on-year
